Document:

Unassociated Document

    EXHIBIT
      10.42

    
      

      

    

     

    NOTE
      PURCHASE AGREEMENT

     

    

    This
      NOTE
      PURCHASE AGREEMENT
      (this
“Agreement”),
      dated
      as of April 26, 2007, is entered into by and among Somanta Pharmaceuticals,
      Inc., a Delaware corporation (the “Company”),
      and
      Access Pharmaceuticals, Inc., a Delaware corporation (the “Lender”).
      

     

    WHEREAS,
      the Lender has agreed to lend to the Company on the date hereof the aggregate
      principal amount of $33,461.89 and may lend to the Company from time to time
      after the date hereof an additional aggregate principal amounts, all as
      hereinbelow provided.

     

    NOW,
      THEREFORE, in consideration of the mutual promises and covenants in this
      Agreement, the parties hereto agree as follows:

     

    1.  (a)  Initial Loan Amount.  On
      the date hereof (the “Closing“),
      the
      Lender shall pay, on behalf of the Company, the initial loan amount of
      $33,461.89 (the “Loan”)
      by
      check or wire transfer pursuant to wire transfer instructions furnished by
      the
      Company. At the Closing, the Company shall issue to the Lender a promissory
      note
      in the form of Exhibit A
      hereto,
      initially reflecting outstanding principal in the amount of the Loan (the
“Note”).
      In
      addition, at the Closing, the Company shall execute, deliver and/or authorize,
      as the case may be, (i) the Patent Collateral Assignment and Security
      Agreement in the form of Exhibit
      B
      hereto
      (the “Patent
      Agreement”),
      (ii) the Trademark Collateral Assignment and Security Agreement in the form
      of Exhibit C
      hereto
      (the “Trademark
      Agreement”),
      (iii) the Security Agreement in the form of Exhibit D
      hereto
      (the “Security
      Agreement”),
      and
      (iv) all other instruments and documents, including, without limitation,
      Uniform Commercial Code financing statements, required to be delivered pursuant
      to the Patent Agreement, the Trademark Agreement and the Security Agreement
      (such other instruments and documents, with the Patent Agreement, the Trademark
      Agreement and the Security Agreement, the “Security
      Documents,”
which
      Security Documents, together with this Agreement, and the Note, are collectively
      referred to herein as the “Loan
      Documents”).

    

    (b) Possible Additional Loan Amounts.  Upon
      a
      request by the Company in the form of Exhibit E
      hereto,
      Lender may, in its sole and absolute discretion, advance additional Loan amounts
      requested by the Company, whereupon Lender shall annotate the Table of Advances
      and Repayment of Principal attached to the Note to record such Loan advance,
      thereby increasing the Loan and the then outstanding principal balance owed
      under the Note by the amount of such advance. The Company hereby authorizes
      Lender to make such annotations and such annotations shall be deemed to be
      amendments to the Note duly authorized and agreed by the Company.

     

    2.  Representations,
      Warranties and Certain Covenants of the Lender.
      The
      Lender hereby represents, warrants and covenants to the Company as to itself,
      as
      follows:

     

    (a)  The
      Lender understands that the offering and sale of the Note are intended to be
      exempt from registration under the Securities Act of 1933, as amended (the
      “Securities Act”),
      by
      virtue of Section 4(2) thereof and the provisions of Regulation D
      promulgated thereunder and, in accordance therewith and in furtherance thereof,
      the Lender further represents and warrants to and agrees with the Company as
      follows:

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

    

    (i)  the
      Lender is purchasing the Note for such Lender’s own account, for investment
      only, and not with a view to, or for sale in connection with, any distribution
      of the Note in violation of the Securities Act, any rule or regulation
      thereunder, or any state securities laws;

     

    (ii)  the
      Lender understands that all documents, records and books pertaining to this
      investment have been made available for inspection by the Lender, the Lender’s
      counsel and/or the Lender’s accountants, the Lender has carefully reviewed all
      such documents, and understands and has relied only on information provided
      to
      such Lender in writing by the Company relating to this investment;

     

    (iii)  the
      Lender and/or the Lender’s advisor(s) have had a reasonable opportunity to ask
      questions of and receive answers from a person or persons acting on behalf
      of
      the Company concerning the offering of the Note, and all such questions have
      been answered to the full satisfaction of such Lender;

     

    (iv)  the
      Lender is not relying on the Company with respect to the investment
      considerations of the Lender relating to this investment;

     

    (v)  the
      Lender (A) will not sell, transfer, pledge, assign or otherwise dispose of
      the
      Note without registration thereof under the Securities Act or pursuant to an
      exemption from registration and, if pursuant to an exemption from registration
      and if requested by the Company, receipt by the Company of an opinion of counsel
      in form and substance satisfactory to the Company and its counsel to the effect
      that such registration is not required, and (B) fully understands and
      agrees that the Lender must bear the economic risk of the Lender’s investment
      for an indefinite period of time because, among other reasons, the Note has
      not
      been registered under the Securities Act or under the securities laws of certain
      states and, therefore, cannot be resold, transferred, pledged, assigned or
      otherwise disposed of unless they are subsequently registered under the
      Securities Act and under the applicable securities laws of such states or unless
      an exemption from such registration is available; and

     

    (vi)  the
      Lender understands that sales or transfers of the Note may be made only in
      compliance with certain state securities laws, and the Note will bear a legend
      reflecting the transfer restrictions imposed thereon and a notation may be
      made
      in the records of the Company restricting the transfer of the Note in a manner
      consistent with the foregoing.

     

    (b)  The
      Lender is an "accredited investor" within the meaning of Rule 501 of
      Regulation D, as promulgated by the Securities and Exchange Commission, as
      presently in effect.

     

    
      
        
        

      

      
        -2-

        
          

        

      

      
        
        

      

       

    

    3.  Representations
      and Warranties of the Company.
      The
      Company hereby represents and warrants to the Lender as follows as of the date
      set forth above (and,
      in
      the event of any advance under the Note, as of the date of any request for
      an
      advance under the Note, as applicable):

     

    (a)  Corporate
      Power; Binding Effect; Non-Contravention.  The
      Company has all requisite power and full legal right to execute and deliver
      this
      Agreement and each of the other Loan Documents, and to perform all of its
      obligations hereunder and thereunder in accordance with the respective terms
      hereof and thereof. The Loan Documents and the transactions contemplated thereby
      have been duly approved and authorized by all requisite corporate action on
      the
      part of the Company, and the Loan Documents have been duly executed and
      delivered by the Company and constitute the legal, valid and binding obligations
      of the Company, enforceable against it in accordance with their respective
      terms. The execution, delivery and performance by the Company of the Loan
      Documents in accordance with their respective terms, and the consummation by
      the
      Company of the transactions contemplated thereby, will not result (with or
      without the giving of notice or the lapse of time or both) in any conflict,
      violation, breach, or default, or the creation of any lien or encumbrance of
      any
      nature (“Liens”)
      upon
      any assets of the Company, (other than pursuant to the Security Documents),
      or
      the termination, acceleration, vesting or modification of any right or
      obligation, under or in respect of (i) the Certificate of Incorporation or
      by-laws of the Company, each as amended to date, (ii) any judgment, decree,
      order, statute, rule, or regulation binding on or applicable to the Company,
      or
      (iii) any agreement or instrument to which the Company is a party or by
      which it or any of its assets is or are bound.

     

    (b) Properties,
      Leases, Etc.  Except
      with respect to Liens in favor of the Lender pursuant to the Security Documents,
      the Company has (A) good and marketable title to all of the assets and
      properties owned by it, free and clear of all Liens, (B) valid title to the
      lessee interest in all assets and properties leased by the Company as lessee,
      free and clear of all Liens, and (C) full right to hold and use all of its
      assets and properties used in or necessary to its businesses and operations,
      in
      each case all free and clear of all Liens, and in each case subject to
      applicable laws and the terms of any lease under which the Company leases such
      assets or properties as lessee. All such assets and properties are in good
      condition and repair, reasonable wear and tear excepted, and are adequate and
      sufficient to carry on the businesses of the Company as presently conducted.
      The
      Company does not own any real property or any interest (other than a leasehold
      interest) in any real property. The Company's leasehold interests are subject
      to
      no Lien, and the Company is in quiet possession of the properties covered by
      such leases. The Company’s leasehold interests are subject to no Lien caused by
      the Company, and the Company is in quiet possession of the properties covered
      by
      such leases.

     

    (c) Tax
      Matters.
      The
      Company has timely filed all tax returns required to be filed by it, each such
      tax return has been prepared in compliance with all applicable laws and
      regulations, and all such tax returns are true and accurate in all material
      respects. All taxes due and payable by the Company have been paid in respect
      of
      any period ending on or before the date hereof, and the Company will not be
      liable for any additional taxes in respect of any taxable period ending on
      or
      before the date hereof in an amount that exceeds the corresponding reserve
      therefor, if any, reflected in the accounting records of the Company as of
      the
      date hereof. No claim has ever been made by a taxing authority in a jurisdiction
      where the Company does not pay tax or file tax returns that the Company is
      or
      may be subject to taxes assessed by such jurisdiction. There are no Liens for
      taxes (other than current taxes not yet due and payable) on the assets of the
      Company. There is no action, suit, taxing authority proceeding, or audit with
      respect to any tax now in progress, pending, or, to the Company's knowledge,
      threatened, against or with respect to the Company. No deficiency or proposed
      adjustment in respect of taxes that has not been settled or otherwise resolved
      has been asserted or assessed by any taxing authority against the Company.
      The
      Company has not consented to extend the time in which any tax may be assessed
      or
      collected by any taxing authority. The Company has not requested or been granted
      an extension of the time for filing any tax return to a date on or after the
      Closing. The Company has withheld and paid all taxes required to have been
      withheld and paid by it in connection with amounts paid or owing to any
      employee, creditor, independent contractor or other third party.

     

    
      
        
        

      

      
        -3-

        
          

        

      

      
        
        

      

       

    

    (d) Governmental
      and Other Third-Party Consents.  Except
      for filings or other notices required by applicable federal and state securities
      laws (which will be completed by the Company within the applicable periods),
      no
      consent, approval or authorization of, or registration, designation, declaration
      or filing with, any governmental authority, federal or other, or any other
      person or entity is required on the part of the Company in connection with
      its
      execution, delivery or performance of this Agreement and the Note and its
      consummation of the transactions contemplated hereby and thereby, or the
      continued conduct of the present business of the Company after the
      Closing.

     

    (e) Compliance
      with Securities Laws.
      Assuming the accuracy of the representations of the Lender contained in
      Section 2 hereof, the offer, issuance and delivery of the Note as
      contemplated by this Agreement are exempt from the registration requirements
      of
      the Securities Act, and are exempt from registration or qualification under
      applicable states' securities laws. Neither the Company nor anyone authorized
      by
      the Company to act on its behalf will hereafter offer to sell, solicit offers
      to
      buy, or sell, any securities of the Company so as to subject the offer, issuance
      and sale of the Note to the registration requirements of the Securities Act.
      

     

    (f) Brokers.  No
      finder, broker, agent or other intermediary has acted for or on behalf of the
      Company in connection with the negotiation or consummation of the transactions
      contemplated hereby, and no fee will be payable by the Company to any such
      person in connection with such transactions.

     

    (g) Disclosure.  No
      representation or warranty by the Company in this Agreement or any other Loan
      Document, in any schedule to this Agreement or any other Loan Document, or
      in
      the Note, contains or will contain any untrue statement of a material fact
      or
      omits or will omit to state a material fact required to be stated herein or
      therein or necessary to make the statements contained herein or therein not
      false or misleading.

     

    (h) Other
      Representations, Warranties and Covenants.  All
      representations, warranties and other statements of fact made by the Company
      in
      the Agreement
      and Plan of Merger, by and among the Company, the Lender and the other parties
      thereto, dated as of April 18, 2007 (the “Merger Agreement”),
      are
      true and correct. The Company has fully performed all of its covenants and
      duties set forth in the Merger Agreement and required to be performed by the
      Company as of the date hereof (and as of the date of any request for an advance
      under the Note, as applicable).

     

    
      
        
        

      

      
        -4-

        
          

        

      

      
        
        

      

       

    

    4.  Indemnification
      by the Company.
      The
      Company agrees to indemnify and hold harmless the Lender and the officers,
      directors, and affiliates and each other person, if any, who controls the Lender
      within the meaning of Section 15 of the Securities Act, from and against any
      and
      all loss, liability, claim, damage and expense whatsoever (including, but not
      limited to, any and all expenses reasonably incurred in investigating, preparing
      or defending against any litigation, commenced or threatened or any claim
      whatsoever) arising out of or based upon any false representation or warranty
      or
      breach or failure by the Company to comply with any covenant or agreement made
      by the Company herein or in any other Loan Document furnished by the Company
      to
      any of the foregoing in connection with this transaction.

     

    5. Miscellaneous
      Provisions.

     

    (a)  Amendments,
      Consents and Waivers.

     

    (i)  This
      Agreement or any provision hereof may be amended or terminated by the agreement
      of the Company and the Lender, and the observance of any provision of this
      Agreement that is for the benefit of the Lender may be waived (either generally
      or in a particular instance, and either retroactively or prospectively), and
      any
      consent, approval, or other action to be given or taken by the Lender pursuant
      to this Agreement, may be given or taken by the waiver, consent, approval or
      other action of the Lender; provided,
      however,
      that
      the Lender may, in writing, waive the benefits of any provision of this
      Agreement.

     

    (ii)  No
      course
      of dealing between the Company and the Lender will operate as a waiver of any
      of
      the Company's or the Lender's rights under this Agreement. No waiver of any
      breach or default hereunder will be valid unless in a writing signed by the
      waiving party. No failure or other delay by any person in exercising any right,
      power, or privilege hereunder will be or operate as a waiver thereof, nor will
      any single or partial exercise thereof preclude any other or further exercise
      thereof or the exercise of any other right, power, or privilege.

     

    
      
        
        

      

      
        -5-

        
          

        

      

      
        
        

      

       

    

    (b)  Notices.
      All
      notices, requests, payments, instructions or other documents to be given
      hereunder will be in writing or by written telecommunication, and will be deemed
      to have been duly given if (i) delivered personally (effective upon
      delivery), (ii) mailed by certified mail, return receipt requested, postage
      prepaid (effective five business days after dispatch), (iii) sent by a
      reputable, established courier service that guarantees overnight delivery
      (effective the next business day) or (iv) dispatched by telecopier if the
      telecopy is received in complete, readable form (effective upon dispatch),
      addressed as follows (or to such other address as the recipient party may have
      furnished to the sending party):

     

    (i)  If
      to the
      Company:

    

    Somanta
      Pharmaceuticals, Inc.

    19200
      Von
      Karman Avenue, Suite 400

    Irvine,
      CA 92612

    Attention:
      Terrance Bruggeman

    Telecopier
      No.: (949) 706-3698

     

    with
      copies sent at the same time and by the same means to:

    

    Adam
      Lenain

    Foley
      & Lardner LLP

    402
      W.
      Broadway, Suite 2100

    San
      Diego, CA 92101

    Attention:  Adam
      Lenain, Esq.

    Telecopier
      No.: (619) 234-3510

    

    (ii)  If
      to
      Lender, to

    

    Access
      Pharmaceuticals, Inc.

    2600
      Stemmons Freeway, Suite 176

    Dallas,
      TX 75207

    Attention:
      Stephen Seiler

    Telecopier
      No.: (214) 905-5101

     

    with
      a
      copy sent at the same time and by the same means to:

     

    Bingham
      McCutchen LLP

    150
      Federal Street

    Boston,
      Massachusetts 02110

    Attention:
      John J. Concannon III, Esq.

    Telecopier
      No. (617) 951-8736

     

    (c)  Counterparts.
      This
      Agreement may be executed by the parties in separate counterparts, each of
      which
      when so executed and delivered will be an original, but all of which together
      will constitute one and the same instrument. In pleading or proving this
      Agreement, it will not be necessary to produce or account for more than one
      such
      complete counterpart.

     

    
      
        
        

      

      
        -6-

        
          

        

      

      
        
        

      

       

    

    (d)  Captions.
      The
      captions of sections or subsections of this Agreement are for reference only
      and
      will not affect the interpretation or construction of this
      Agreement.

     

    (e)  Binding
      Effect and Benefits.  This
      Agreement will bind and inure to the benefit of the parties hereto and their
      respective successors and permitted assigns. Except as otherwise provided in
      this Agreement, the provisions of this Agreement that are for the Lender's
      benefit will inure to the benefit of all permitted transferees of the Note,
      and
      the applicable provisions of this Agreement that bind the Lender will bind
      all
      transferees of the Note. Nothing in this Agreement is intended to or will confer
      any rights or remedies on any person other than the parties hereto and their
      respective successors and permitted assigns.

     

    (f)  Assignment.
      This
      Agreement and the rights and obligations hereunder may not be assigned by the
      Company without the prior written consent of the Lender in their sole and
      absolute discretion. This Agreement and the rights and obligations hereunder
      and
      under the Note may be transferred by the Lender in the Lender’s sole discretion
      at any time, in whole or in part, including, without limitation, to affiliates
      of the Lender, without the consent of any other party hereto.

     

    (g)  Further
      Assurances.  From
      time to time on and after the Closing, the Company will promptly execute and
      deliver all such further instruments and assurances, and will promptly take
      all
      such further actions, as the Lender may reasonably request in order more
      effectively to effect or confirm the transactions contemplated by this Agreement
      and/or any of the Loan Documents and to carry out the purposes hereof and
      thereof.

     

    (h)  Severability.
      No
      invalidity or unenforceability of any section of this Agreement or any portion
      thereof will affect the validity or enforceability of any other section or
      the
      remainder of such section.

     

    (i)  Entire
      Agreement.  This
      Agreement, together with the exhibits and schedules hereto and the Loan
      Documents, contains the entire understanding and agreement among the parties,
      or
      between or among any of them, and supersedes any prior understandings or
      agreements between or among any of them, with respect to the subject matter
      hereof.

     

    (j)  Governing
      Law; Consent to Jurisdiction.
      This
      Agreement will be governed by and interpreted and construed in accordance with
      the internal laws of the Commonwealth of Massachusetts, without regards to
      conflicts of laws principles. The
      Company agrees that any action or claim arising out of any dispute in connection
      with this Agreement, any rights or obligations hereunder or the performance
      or
      enforcement of such rights or obligations may be brought in the courts of the
      Commonwealth of Massachusetts or any federal court sitting therein, and consents
      to the non-exclusive jurisdiction of such court and to service of process in
      any
      such suit being made upon the Company by mail at the address specified herein.
      The Company hereby waives any objection that it may now or hereafter have to
      the
      venue of any such suit or any such court or that such suit is brought in an
      inconvenient court.

     

    
      
        
        

      

      
        -7-

        
          

        

      

      
        
        

      

       

    

    (k) Waiver
      of Jury Trial.  THE
      COMPANY WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM
      ARISING OUT OF ANY DISPUTE IN CONNECTION WITH THIS AGREEMENT, ANY RIGHTS OR
      OBLIGATIONS HEREUNDER OR THE PERFORMANCE OR ENFORCEMENT OF ANY SUCH RIGHTS
      OR
      OBLIGATIONS. Except as prohibited by law, the Company waives any right which
      it
      may have to claim or recover in any litigation referred to in the preceding
      sentence any special, exemplary, punitive or consequential damages or any
      damages other than, or in addition to, actual damages. The Company
      (a) certifies that the Lender nor any representative, agent or attorney of
      the Lender has represented, expressly or otherwise, that the Lender would not,
      in the event of litigation, seek to enforce the foregoing waivers or other
      waivers contained in this Agreement, and (b) acknowledges that, in entering
      into
      this Agreement and the other Loan Documents to which the Lender is a party,
      the
      Lender is relying upon, among other things, the waivers and certifications
      contained in this paragraph. 

     

    (l) Expenses.
      The
      Company agrees to pay on demand all costs and expenses, including reasonable
      fees and disbursements of a single counsel for the Lender, incurred in
      connection with the negotiation, preparation, execution and delivery of the
      Loan
      Documents and the consummation of the transactions contemplated thereby, and
      all
      costs and expenses, including reasonable fees and disbursements of a single
      counsel for the Lender, incurred in connection with any amendments to or waivers
      under or in respect of the Loan Documents from time to time.

     

    

    [Signatures
      on Following Page.]

    

    
      
        
        

      

      
        -8-

        
          

        

      

      
        
          

        

      

    

    IN
      WITNESS WHEREOF, the Company and the Lender have duly executed this Agreement
      as
      an agreement under seal on and as of the date first above written.

     

    
      	 COMPANY:	 SOMANTA PHARMACEUTICALS,
              INC.
	 	 
	 	 
	 	 By:	 /s/ Terrance
              J. Bruggeman	
            
	 	 	 Name: Terrance J. Bruggeman 
	 	 	 Title: Executive Chairman
	 	 	 
	 	 	 
	 LENDER: 	 ACCESS PHARMACEUTICALS,
              INC.
	 	 	 
	 	 By:	 /s/
              Stephen R. Seiler 	
            
	 	 	 Name: Stephen R. Seiler
	 	 	 Title: President and Chief Executive
              Officer

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    

    Exhibit
      A

    

    

    Form
      of Note

    (See
      attached.)

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Exhibit
      B

    

    

    Form
      of Patent Collateral Assignment and Security Agreement

    (See
      attached.)

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Exhibit
      C

    

    

    Form
      of Trademark Collateral Assignment and Security Agreement

    (See
      attached.)

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Exhibit
      D

    

    

    Form
      of Security Agreement

    (See
      attached.)

    

    

    
       

      
        
        

        
          

        

      

      
        
        

      

    

    Exhibit
      E

    

    

    Form
      of Request for Loan Advance

    

    

    Access
      Pharmaceuticals, Inc.

    2600
      Stemmons Freeway, Suite 176

    Dallas,
      TX 75207

    Attention:
      Stephen Seiler

    

    

    Dear
      Mr.
      Seiler:

    

    Somanta
      Pharmaceuticals, Inc. (the “Borrower”)
      hereby
      requests that Access Pharmaceuticals, Inc. (the “Lender”)
      advance
      the principal amount set forth below, under the promissory note, executed and
      delivered to by the Borrower as of April 26, 2007 (the “Note”).

    

    
      	
               

              Amount
                of Advance Requested

            	
               

              Wire
                Instructions

            	
              Date
                Advance is Requested to Be Made

            
	 	 	 
	 	 	 

    

    

    In
      the
      event the Lender agrees to, and does, advance any amount requested hereunder,
      Borrower hereby requests that the Lender amend the Note and annotate the
Table
      of
      Advances and Repayment of Principal attached to the Note to reflect such amount
      as an additional principal amount payable thereunder.

    

    Sincerely,

    

    Somanta
      Pharmaceuticals, Inc.

    

    

    By:
      __________________________

    Name:

    Title:

    

    Date:
      ________________________ex10-1.htm

    Exhibit
      10.1

    

    Second
      Addendum to Lease dated April 1, 2003 by and between Enterprise Informatics,
      Inc. (“Lessee”) and Mesa Ridge Center, LLC (“Lessor”) at 10052 Mesa Ridge Court,
      San Diego, Ca  92121.

    

    

    1.           Reduced
      Premises:  The Premises known as Suite 100 shall consist of 6,996
      rentable square feet on the first floor as shown in Exhibit A of this Second
      Amendment to Lease.

    

    2.           Term:  The
      Term of the Lease for the Reduced Premises shall be from July 1, 2007 and expire
      on June 30, 2012.

    

    
      	
              3.  

            	
              Base
                Rent:  The Monthly Base Rent shall be as
                follows:

            

    

    

    July
      1,
      2007 – June 30,
      2008                                                                $13,642.20
      plus separately metered electrical ($1.95 RSF)

    July
      1,
      2008 – June 30,
      2009                                                                $14,119.67
      plus separately metered electrical ($2.02 RSF)

    July
      1,
      2009 – June 30,
      2010                                                                $14,626.53
      plus separately metered electrical ($2.04 RSF)

    July
      1,
      2010 – June 30,
      2011                                                                $15,111.36
      plus separately metered electrical ($2.16 RSF)

    July
      1,
      2011 – June 30,
      2012                                                                $15,640.25
      plus separately metered electrical ($2.24 RSF)

    

    
      	
              4.  

            	
              Lessee’s
                Share of Operating Expenses:  Lessee’s share shall be
                fifteen and six tenths percent (15.6%). 2007 shall be utilized as
                the new
                base year for operating expense
                increases.

            

    

    

    
      	
              5.  

            	
              Vehicle
                Parking:  Twenty-seven (27)
                spaces.

            

    

    

    6.  Tenant
      Improvements:  Lessor shall pay for the cost of demising the space
      including separating the HVAC and electrical.  Lessor shall also
      remove the walls and provide glass sidelights according to the Exhibit A Floor
      Plan. Lessor and Lessee shall split the cost of replacing up to 3,000 square
      feet of carpeting. Lessee shall be responsible for any additional improvements
      within their Premises.

    

    7.           Lessee’s
      Termination Payment:  Lessor agrees to remit to Lessee upon
      Lessee’s vacating the previously occupied 5,196 rentable square feet the sum of
      $11,476.38 which represents the proportionate share of the termination payment
      retained by Lessor pertaining to the space being retained by
      Lessee.

    

    8.           Option
      to Renew:  Lessor does not have an Option to Extend the
      lease.

    

    

    

    
      	
              Lessor:

              Mesa
                Ridge Center, LLC

            	 	
              Lessee:  Enterprise
                Informatics Inc.

            
	 	 	 
	 	 	 
	
              By:

            	
              /s/George
                R. Percy

            	 	
              By:

            	
              /s/
                Alan Kiraly

            
	
              Print
                Name:

            	
              George
                R. Percy

            	 	
              Print
                Name:

            	
              Alan
                Kiraly

            	 
	
              Title:

            	
              Prncipal

            	 	
              Title:

            	
              CEO

            	 
	
              Date:

            	
              June
                14, 2007

            	 	
              Date:

            	
              June
                14, 2007

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]